Related Experiment Video
Updated: Jan 18, 2026

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Super Responder of 177 Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis
Khulood Al Riyami1, Anjali Jain, Asiya Al Busaidi
1Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.
Abstract:
PSMA-targeted radioligand therapies with 177 Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.4GBq of 177 Lu-PSMA-617, 6 weeks apart. There was complete resolution of prior 68 Ga-PSMA avid lesions, a significant decrease in serum PSA level, and symptomatic response after therapy. We suggest that patients with ESRD on dialysis can be safely treated with 177 Lu-PSMA radionuclide therapy.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Hemodialysis III: Nursing Management

